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TOR2, suggesting that the functions of the rapamycin-
sensitive regulatory pathway(s) governed by TOR were
highly conserved in eukaryotic cells.
The TOR proteins are members of the phosphoinosi-
tide (PI) 3-kinase related kinase (PIKK) family, which
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includes mammalian ATM, ATR, and DNA-PK (TibbettsLa Jolla, California 92037
and Abraham, 2000). Like other PIKK family members,
the TORs are large polypeptides (280–300 kDa) that bear
a carboxy-terminal region with sequence similarity toThe Target of Rapamycin (TOR) proteins function in
the catalytic domains of PI3-kinases. In spite of thesignaling pathways that promote protein synthesis
similarity to lipid kinases, the PIKK family members thatand cell growth. In yeast, TOR signaling is regulated
possess active kinase domains phosphorylate proteinsby nutrient availability, whereas in metazoan cells TOR
on Ser or Thr residues. The consensus phosphorylationactivities may be controlled by both nutrients and
site for all PIKK family members (except the TORs) isgrowth factors. The recent identification of novel TOR-
Ser/Thr followed by Gln at the1 position. The preferredinteracting proteins has provided crucial insights into
sequence motif for the TORs remains unclear; however,TOR regulation and function.
known in vitro substrates contain Ser/Thr followed by
Pro or a hydrophobic amino acid at the 1 position.A recent strategy, termed “chemical genetics,” involves
The lack of a consensus motif for substrate recognitionthe use of drugs or other bioactive compounds as
by TOR kinases hints that these PIKK family membersprobes for the dissection of signaling pathways. The
may rely on an alternative mechanism for substrate iden-application of small molecules to intact cells has uncov-
tification or regulation in intact cells.ered regulatory mechanisms that would have been diffi-
In yeast, TOR gene depletion or rapamycin exposurecult to elucidate with traditional genetic techniques, par-
triggers a stress response program that strongly resem-ticularly in mammalian systems. To appreciate the
bles the nutrient starvation phenotype. These observa-investigative power of chemical genetics, one need only
tions provided the first indication that TOR signalingexamine the history of rapamycin, a bacterially derived
coordinates nutrient availability with cell growth anddrug that holds great promise in several clinical settings.
proliferation. TOR1 and TOR2 are functionally redundantIn the late 1970’s, rapamycin was identified as a potent
in this nutrient response pathway, but TOR2 carries outantifungal and immunosuppressive agent (Abraham and
an additional, rapamycin-insensitive function related toWiederrecht, 1996). The drug was clinically approved for
the control of the actin cytoskeleton that is essential foruse in kidney transplant patients in 1999, and additional
yeast cell viability (Schmelzle and Hall, 2000). Investiga-applications in autoimmune and chronic inflammatory
tors using rapamycin as a research tool should takediseases are at various stages of testing. Two rapa-
heed of these observations, which indicate that rapa-mycin-related drugs, CCI-779 (Wyeth-Ayerst) and
mycin is a selective, rather than global, inhibitor of TORRAD001 (Novartis), have also generated considerable
function in eukaryotic cells.excitement in both the clinical and basic research can-
Other evidence suggests that mTOR activity is alsocer communities. In addition, CCI-779 displays remark-
regulated by nutrient availability. Transfer of cultured
able efficacy in the prevention of restenosis after coro-
mammalian cells from standard growth medium into
nary artery interventions with stent implantation. Thus
amino acid- and/or glucose-free medium leads to rapid
rapamycin and its analogs have clinical potential in three dephosphorylation of two known mTOR substrates, 4E-
major therapeutic arenas: organ transplantation, cancer, BP1 (PHAS-I) and S6K1 (p70 S6 kinase) (Gingras et al.,
and cardiovascular disease. 2001). In the dephosphorylated state, 4E-BP1 binds av-
Seminal insights into rapamycin’s mechanism of ac- idly to eIF-4E, thereby suppressing cap-dependent pro-
tion emerged from studies in Saccharomyces cerevisiae tein synthesis. Restoration of nutrients provokes
(for review, see Schmelzle and Hall, 2000). Screens for multisite phosphorylation of 4E-BP1 by mTOR (and pos-
mutations that rendered S. cerevisiae resistant to the sibly other protein kinases), release of eIF-4E, and re-
growth-inhibitory effects of rapamycin identified two sumption of cap-dependent translation. Similarly, S6K1
highly homologous Target of Rapamycin (TOR) proteins, activity is repressed in starved cells, and nutrient stimu-
TOR1 and TOR2. The interaction between the drug and lation leads to its phosphorylation and activation. Acti-
each TOR protein was contingent on the formation of a vated S6K1 stimulates ribosome biogenesis, which
pharmacologically active complex between rapamycin upregulates the translational capacity of the cell. Thus,
and its intracellular receptor, FK506-binding protein of mTOR is a central component of a rapamycin-sensitive
12 kDa (FKBP12). The identification of this complex as signaling pathway that coordinates protein synthesis
the proximate TOR ligand enabled purification of mam- with glucose and amino acid availability.
malian TOR (mTOR) from tissue extracts. The amino In contrast to yeast, mammalian cell proliferation in
acid sequence of mTOR (also known as FRAP or RAFT1) tissues may be controlled by the supply of growth fac-
is remarkably homologous to those of yeast TOR1 and tors rather than nutrients, because body metabolism
strives to maintain nutrient homeostasis in tissues.
Some investigators argue that mTOR is strictly tied to1Correspondence: abraham@burnham.org
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the nutrient-sensing pathway and that mitogenic signals mTOR immunoprecipitates in Tween-20-containing buffer
and “inactivated” (dissociated) the immunoprecipitatesemanating from growth factor receptors provide paral-
lel, independent inputs into both the translational and by washing with NP-40-containing buffer. Their NP-40
eluate contained a protein whose primary sequence wascell cycle progression machinery. This unidirectional
model for afferent signaling to mTOR is far from proven. identical to that of raptor.
Human raptor contains a unique amino-terminal “rap-For example, the biochemical pathway through which
changes in glucose and amino acid concentrations com- tor N-conserved” (RNC) region (Kim et al., 2002) followed
by three HEAT repeats and seven WD domains, the lattermunicate with the TOR proteins has not been defined.
Second, the strongest experiments supporting this spanning the carboxy-terminal one-third of the protein.
Thus, the domain structure of raptor is consistent withmodel typically involve starvation in amino acid- and/or
glucose-free medium, followed by acute readdition of a role as an adaptor in multiprotein complexes. Kim et
al. found that raptor is stoichiometrically associated withnutrients. Although mTOR-dependent signaling events
are then observed, the conditions do not mimic the more mTOR, suggesting that it is an obligate subunit of all
mTOR complexes.moderate fluctuations in nutrient levels that occur physi-
ologically. Perhaps mTOR activity is constitutively active To show that raptor is a critical regulator of mTOR
function, Kim et al. (2002) used small-interfering RNAin tissue cells unless there is a pathological insult, such
as loss of blood supply due to vascular occlusion or (siRNA) technology to knock down raptor expression in
human cells; the phenotypic consequences of raptorhemorrhage.
An alternative model for mTOR regulation posits that deficiency (i.e., inhibition of amino acid-induced S6K1
activation and a reduction in cell size) were qualitativelymetazoan evolution has linked mTOR function to hor-
mone-dependent mitogenic signals, in addition to a pri- similar to those induced by either siRNA-mediated
mTOR depletion or treatment with rapamycin. Hara etmordial nutrient response pathway. Indeed, PI3-kinase
and its downstream target, AKT, have emerged as solid al. (2002) used an immune complex kinase assay as the
readout for mTOR function and found that raptor bindscandidates for the regulation of mTOR function in growth
factor-stimulated cells (Mills et al., 2001; Nave et al., directly to 4E-BP1 and S6K1. Additional results support
a model in which raptor functions as a bridging protein1999; Sekulic et al., 2000). However, critics of the growth
factor model for mTOR regulation rightfully argue that that presents 4E-BP1 and S6K1 (and possibly additional
substrates) to the mTOR kinase domain for phosphory-the supporting evidence is purely correlative, and in-
deed is contradicted by genetic studies in Drosophila, lation. The substrate-scaffolding model nicely explains
the earlier finding that nonionic detergents inhibit 4E-which placed PI3-kinase and dTOR in parallel pathways
(Montagne et al., 1999; Radimerski et al., 2002). BP1 phosphorylation by mTOR; since these detergents
dissociate raptor, they block the raptor-dependent pre-The controversies surrounding mTOR regulation and
function stem in part from the paucity of information sentation of 4E-BP1 to mTOR.
The common message from the Cell papers on mam-regarding the proteins that communicate directly with
mTOR (and yeast mTORs, for that matter). This situation malian raptor is that its association with mTOR is re-
quired for the optimal phosphorylation of 4E-BP1 andhas now been addressed in dramatic fashion with the
publication of three landmark reports that unveil a series S6K1 in nutrient-stimulated cells. That raptor and TOR
reside in the same signaling pathway is supported byof TOR-interacting proteins in yeast and mammalian
cells. The notion that the TORs function in multiprotein genetic analyses in C. elegans (Hara et al., 2002). In other
respects, however, these studies have some significantcomplexes was founded in part on structural homology
predictions. The large amino-terminal regions (2000 discrepancies. Sabatini and coworkers found that the
stability of the raptor-mTOR complex was increasedamino acids) of these proteins contain at least 20 HEAT
repeats, which form -helical structures and provide when cells were amino acid or energy starved (Kim et
al., 2002). The transition to this “tight” complex corre-hydrophobic surfaces favorable for protein-protein in-
teractions. lated with the inhibition of mTOR-dependent signaling
in cells and with the repression of mTOR kinase activityThe authors of all three studies used mass spectrome-
try to identify proteins that coprecipitated with TORs in vitro. Notably, the stability of the mTOR-raptor com-
plex was not modulated by polypeptide growth factors,from yeast or mammalian cell extracts. Crucial to their
success was the method of sample preparation prior to which suggests that raptor is selectively involved in the
relay of nutrient-derived signals to mTOR. From theseimmunoprecipitation. Sabatini and coworkers surmised
that mTOR-containing complexes might be prone to dis- observations, Kim et al. concluded that raptor is a bidi-
rectional modulator, inhibiting mTOR under nutrient-sociate in buffer containing nonionic detergent. To counter
this tendency, they added a reversible chemical cross- poor conditions and activating it when adequate sup-
plies of amino acids and carbohydrates are available.linker to their lysis buffer to stabilize interactions be-
tween mTOR and putative partner proteins. This strat- Although this model of interplay between mTOR and
raptor is appealing, Yonezawa and colleagues, studyingegy yielded a novel 150 kDa polypeptide, which they
termed regulatory associated protein of mTOR (raptor). the same protein-protein interaction, obtained no evi-
dence for changes in raptor-mTOR complex stabilityOn the other hand, it was known that the in vitro
kinase activity of mTOR toward 4E-BP1 and S6K1 was when cells were shifted between nutrient-rich and nutri-
ent-poor media (Hara et al., 2002). The reason for thisunusually sensitive to nonionic detergents such Triton
X-100 or NP-40 (Brunn et al., 1997; Isotani et al., 1999), discrepancy may be linked to the different detergent
conditions used by the two laboratories in preparing thealthough significant substrate phosphorylation was
observed in the presence of Tween-20. Accordingly, cellular extracts; the buffer used by Sabatini may have
distinguished two affinity states for the mTOR-raptorYonezawa and colleagues prepared putative “active”
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Figure 1. TOR Signaling Complexes in Eu-
karyotic Cells
The left side of the figure depicts the TORC1
and TORC2 complexes, which mediate cellu-
lar responses to nutrient availability and en-
ergy production. In mammalian TORC1, rap-
tor may serve as a scaffolding subunit that
binds S6K1 and 4E-BP1 and facilitates their
phosphorylation by the mTOR kinase domain.
The TORC2 complex plays an essential role in
actin polarization and cell viability in budding
yeast, but may have no direct mammalian
homolog. The right side outlines a tentative
pathway that links mitogen-dependent AKT
activation to the stimulation of TOR-depen-
dent responses in Drosophila and mamma-
lian cells. The TSC complex serves as a nega-
tive modulator of this pathway and may
function via direct interactions with dTOR/
mTOR or by blocking the access of these
TORs to their downstream target proteins.
complex, whereas that employed by Yonezawa could phorylation by the mTOR catalytic domain. The key dif-
ference here may be that Kim et al. used a fragment ofnot do so. Furthermore, Hara et al. performed assays
largely with transiently transfected cells that overex- S6K1 as the phosphoacceptor in their kinase assays,
whereas Hara et al. (2002) used full-length S6K1 or 4E-pressed raptor and/or mTOR, whereas Kim et al. studied
endogenous mTOR-raptor complexes in human cells. BP1. If the assertion that raptor functions as a substrate
scaffold for mTOR is true, then it is possible that theOverexpression of raptor and mTOR could be a signifi-
cant issue, because additional mTOR-interacting pro- S6K1 fragment used by the Sabatini group simply lacks
the putative raptor binding region. Consequently, phos-teins may contribute to the stability of the endogenous
mTOR-raptor complexes in untransfected cells (see be- phorylation of the S6K1 fragment by mTOR would ap-
pear to be raptor independent, and might depend in-low; Loewith et al., 2002). Obviously, important technical
differences need to be addressed before firm conclu- stead on passive diffusion of the substrate into the active
site of the mTOR kinase domain. In this setting, thesions regarding the impact of nutrient status on the
stability of the mTOR-raptor complex in mammalian presence of bound raptor might actually interfere with
the access of GST-S6K1 fragment to the mTOR activecells can be drawn.
Similar uncertainty surrounds the effect of rapamycin site. Indeed, this model accommodates Kim et al.’s ob-
servation that exposure of mTOR to Triton X-100, whichon the mTOR-raptor interaction. Given that rapamycin
treatment induces a starvation-like phenotype, one effectively strips raptor from mTOR, strongly activates
mTOR kinase activity toward the GST-S6K1 substrate.might expect that the drug would increase the stability
of the mTOR-raptor complex in nutrient-replete cells. Kim et al. also reported that raptor overexpression inhib-
its mTOR function in intact cells. Although these findingsInstead, Kim et al. (2002) found that cellular exposure
to rapamycin severely weakened this complex, more are consistent with the idea that raptor dampens mTOR
signaling in vivo, the overexpression of a putative sub-so in the presence of nutrients than in their absence.
However, Hara et al. (2002) again found no effect of strate-scaffolding protein could suppress mTOR func-
tion indirectly by sequestering its intracellular substratesrapamycin on the stability of the complex. Loewith et
al. (2002) also examined this issue and concurred with in nonproductive complexes.
Direct experimentation is required to rationalize thethe negative result of the Yonezawa group. Although it
is tempting to go with the majority opinion (i.e., discrepant results obtained by the two teams. However,
the scaffolding model for raptor function is made evenFKBP12•rapamycin binding does not alter the raptor-
mTOR interaction), additional experimentation is needed more attractive by the recent identification of a common,
5 amino acid TOR-signaling (TOS) motif in 4E-BP1 andbefore the model proposed by Sabatini and coworkers
is accepted or overturned. S6K1 (Schalm and Blenis, 2002). An intact TOS se-
quence is required for mTOR-dependent phosphoryla-A final fundamental discrepancy between the two Cell
reports concerns the role of raptor as a regulator of tion of both proteins following nutrient readdition to
starved cells. It will be interesting to learn whether themTOR kinase activity: dual activator/repressor or activa-
tor only? Once again, the different conclusions of the TOS motif serves as a docking site for raptor in mamma-
lian cells.two laboratories may stem from seemingly minor differ-
ences in their experimental approach. Hara et al. (2002) In a spectacular report that followed on the heels of
the Cell papers, Michael Hall’s laboratory has identifiedobserved that coprecipitation of raptor with mTOR was
essential for the phosphorylation of 4E-BP1 and S6K1 five proteins that coprecipitate with S. cerevisiae TOR1
and/or TOR2; one of these proteins, named KOG1 (Kon-in immune complex kinase assays. In contrast, Kim et
al. (2002) found that mTOR kinase activity was inversely troller of Growth-1), is the budding yeast homolog of
raptor.related to the amount of coprecipitating raptor, which
indicated that raptor could interfere with substrate phos- Loewith et al. (2002) resolved two structurally and
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functionally distinct TOR complexes (TORCs) (see Fig- PTEN), AKT phosphorylates TSC2, and this modification
ure 1). TORC1 contains either TOR1 or TOR2, together relieves the mTOR-repressive function of the TSC com-
with KOG1, and binds FKBP12•rapamycin. TORC2 con- plex. Whether TSC binds to the raptor-mTOR complex
tains TOR2 exclusively and has four additional subunits, (i.e., mammalian TORC1) or yet another TORC in mam-
one of which (LST8) is shared with TORC1, whereas the malian cells remains an important but unanswered ques-
others (AVO1, AVO2, and AVO3) are uniquely present in tion. With many new TOR partners now in hand, we
TORC2. Strikingly, TOR2 fails to bind FKBP12•rapa- should see a quick resolution to some long-standing
mycin in the context of TORC2. Hence, TORC2 is a questions and controversies surrounding TOR signaling,
strong candidate for the transmission of rapamycin- and undoubtedly a few more surprises as well.
insensitive signals leading to actin cytoskeleton reorga-
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an autosomal dominant disease that is characterized
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(hamartin) or TSC2 (tuberin). In response to growth fac-
tor stimulation (or oncogenic insults such as loss of
